Online first
Letter to the Editor
Published online: 2024-09-17
SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes
DOI: 10.5603/cj.102158
Pubmed: 39287154
Abstract
Not available
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24): 2221–2232.
- Jankowski P, Kozieł P, Pająk A. Body mass index and waist circumference in patients with established coronary artery disease over a 20-year period. Cardiol J. 2023; 30(1): 150–152.
- Płaczkiewicz-Jankowska E, Czupryniak L, Gajos G, et al. Management of obesity in the times of climate change and COVID-19: an interdisciplinary expert consensus report. Pol Arch Intern Med. 2022; 132(3).
- Tirandi A, Montecucco F, Carbone F, et al. Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease. Pol Arch Intern Med. 2024; 134(2).
- Kahn SE, Deanfield JE, Jeppesen OK, et al. SELECT Trial Investigators. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. 2024; 47(8): 1350–1359.
- Lingvay I, Deanfield J, Kahn SE, et al. SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024; 47(8): 1360–1369.
